2561 Stock Overview

An investment holding company, engages in the development and commercialization of endocrine therapies in the People’s Republic of China, Hong Kong, and Taiwan. More details

2561 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 53.8% per year

Analysts in good agreement that stock price will rise by 84.8%

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (CN¥3M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

VISEN Pharmaceuticals Competitors

Price History & Performance

Summary of share price highs, lows and changes for VISEN Pharmaceuticals
Historical stock prices
Current Share Price	HK$44.55
52 Week High	HK$69.15
52 Week Low	HK$39.25
Beta	0
1 Month Change	-1.33%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-35.25%

Recent updates

Shareholder Returns

	2561	HK Biotechs	HK Market
7D	-3.0%	3.1%	-0.6%
1Y	n/a	80.2%	18.9%

Return vs Industry: Insufficient data to determine how 2561 performed against the Hong Kong Biotechs industry.

Return vs Market: Insufficient data to determine how 2561 performed against the Hong Kong Market.

Price Volatility

Is 2561's price volatile compared to industry and market?
2561 volatility
2561 Average Weekly Movement	10.8%
Biotechs Industry Average Movement	13.0%
Market Average Movement	7.9%
10% most volatile stocks in HK Market	14.9%
10% least volatile stocks in HK Market	4.2%

Stable Share Price: 2561 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: Insufficient data to determine 2561's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	58	Pony Lu	www.visenpharma.com/cn

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of endocrine therapies in the People’s Republic of China, Hong Kong, and Taiwan. Its lead product, Lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. The company also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism.

VISEN Pharmaceuticals Fundamentals Summary

How do VISEN Pharmaceuticals's earnings and revenue compare to its market cap?
2561 fundamental statistics
Market cap	HK$5.08b
Earnings (TTM)	-HK$198.56m
Revenue (TTM)	HK$3.03m

1,678x

P/S Ratio

-25.6x

P/E Ratio

Is 2561 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2561 income statement (TTM)
Revenue	CN¥2.78m
Cost of Revenue	CN¥0
Gross Profit	CN¥2.78m
Other Expenses	CN¥185.02m
Earnings	-CN¥182.24m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.60
Gross Margin	100.00%
Net Profit Margin	-6,562.55%
Debt/Equity Ratio	0%

How did 2561 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/06/02 23:16
End of Day Share Price	2025/06/02 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

VISEN Pharmaceuticals is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Zhu Chen	Citic Securities Co., Ltd.
Chu Wang	Jefferies LLC
Po Han Lin	Morgan Stanley

VISEN Pharmaceuticals SEHK:2561 Stock Report